The Coalition for Epidemic Preparedness Innovations (CEPI) has committed up to US$61.8 million to accelerate development and production of three vaccine candidates targeting the Bundibugyo strain of Ebola virus disease. This investment, announced on June 1, 2026, comes as outbreaks of hantavirus and Bundibugyo Ebola—for which no proven vaccines yet exist—continue to unfold. CEPI pools both public and philanthropic resources to advance epidemic and pandemic preparedness.
The absence of approved vaccines for these specific pathogens highlights a critical gap in global health security. CEPI's mandate is to ensure that research and development benefits all countries, not just wealthy ones. The current investment aims to rapidly move these candidates through testing and into production.
Detailed financial terms show CEPI will allocate the full $61.8 million to advance three Bundibugyo-specific vaccine candidates. No additional breakdown of funding per candidate or timeline for clinical trials has been disclosed. CEPI typically requires cost-sharing from partners and transparency in pricing and access.
The success of this initiative could reshape how the world responds to neglected tropical viruses that disproportionately affect low-income nations. If any candidate proves effective, it would be the first licensed vaccine for Bundibugyo Ebola. However, manufacturing scale-up and equitable distribution remain formidable hurdles.
Critics have raised concerns about the lack of transparency in CEPI's previous vaccine deals and whether such investments truly reach underserved populations. The organization has pledged greater openness but has yet to release detailed access commitments for this specific funding round.